NCT02920190

Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.

Conditions

• Monoclonal Gammopathies
• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Liraglutide	1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months

Timeline

• Start date: 2020-09-01
• Primary completion: 2021-09-01
• Completion: 2021-12-31
• First posted: 2016-09-30
• Last updated: 2020-09-21

Regulatory

• FDA-regulated drug study